Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Terns Pharmaceuticals, Inc. (NASDAQ:TERNGet Free Report) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $14.50.

A number of brokerages have recently issued reports on TERN. JMP Securities reissued a “market outperform” rating and set a $15.00 target price on shares of Terns Pharmaceuticals in a research note on Tuesday, April 30th. HC Wainwright reaffirmed a “neutral” rating and issued a $5.50 price target on shares of Terns Pharmaceuticals in a report on Tuesday, May 14th. BMO Capital Markets upped their target price on Terns Pharmaceuticals from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, March 15th. Finally, UBS Group lowered their price target on shares of Terns Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 27th.

Read Our Latest Stock Report on TERN

Terns Pharmaceuticals Stock Up 10.6 %

TERN stock opened at $7.53 on Tuesday. The business’s 50-day moving average price is $6.54 and its 200-day moving average price is $6.35. The stock has a market cap of $487.04 million, a P/E ratio of -5.98 and a beta of -0.37. Terns Pharmaceuticals has a twelve month low of $3.26 and a twelve month high of $8.68.

Terns Pharmaceuticals (NASDAQ:TERNGet Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. On average, equities research analysts expect that Terns Pharmaceuticals will post -1.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several large investors have recently bought and sold shares of TERN. Price T Rowe Associates Inc. MD boosted its holdings in shares of Terns Pharmaceuticals by 12.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 20,694 shares of the company’s stock valued at $136,000 after acquiring an additional 2,261 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Terns Pharmaceuticals by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,889 shares of the company’s stock worth $78,000 after acquiring an additional 4,742 shares during the last quarter. AJOVista LLC acquired a new position in Terns Pharmaceuticals in the 4th quarter valued at about $58,000. Bleakley Financial Group LLC purchased a new position in shares of Terns Pharmaceuticals during the fourth quarter valued at approximately $68,000. Finally, Simplicity Solutions LLC acquired a new stake in shares of Terns Pharmaceuticals during the fourth quarter worth $68,000. Institutional investors and hedge funds own 98.26% of the company’s stock.

About Terns Pharmaceuticals

(Get Free Report

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

See Also

Analyst Recommendations for Terns Pharmaceuticals (NASDAQ:TERN)

Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.